Adding L-Carnitine and Selenium to Methimazole in Graves' Disease: A Prospective Randomized Trial on Thyroid Markers and Quality of Life

What Was Tested

The paper reports a study of L-Carnitine, published as a randomized controlled trial.

Based on the nuclear antagonistic properties of L-carnitine (LCT) on thyroid hormone action and the immunomodulatory role of selenium (Se), the researchers aimed to assess the impact of adding a combined LCT and Se supplement to standard methimazole (MMI) therapy on the biochemical profile and quality of life (QoL) of patients with overt GD.

Why It Was Studied

Background: The therapeutic response in Graves' Disease (GD) remains largely unpredictable.

Patients often experience persistent symptoms that are poorly correlated with thyroid hormone levels, an undefined treatment duration, and the need for long-term or definitive therapies.

Who Took Part

According to the abstract, 60 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Participants were randomized to receive either standard treatment with MMI alone (Control Group) or MMI plus the combined LCT/Se supplement (Intervention Group).

How the Study Was Run

The researchers set it up as a randomized and multicenter study.

Random assignment meant chance, not the researchers, decided who got L-Carnitine and who got the comparison, which limits bias.

More than one site took part, so the patients came from several places.

The methods mention a period of 24 months.

TSH, fT3, fT4, and TSH-receptor antibodies (TRAb) levels were evaluated every two months for up to 24 months or until spontaneous remission or definitive therapy.

What Was Measured

Patients often experience persistent symptoms that are poorly correlated with thyroid hormone levels, an undefined treatment duration, and the need for long-term or definitive therapies.

At each visit, patients completed a symptom questionnaire addressing the frequency of typical thyrotoxic symptoms.

The subject headings attached to it are Methimazole, Graves Disease, Carnitine, Quality of Life, Selenium, Antithyroid Agents and Biomarkers.

The authors tagged it with the keywords Graves’ disease and hyperthyroidism.

What This Means in Plain Language

The paper is a randomized and multicenter study of L-Carnitine in 60 patients over 24 months.

The publication is from 2025 (Nutrients), a journal based in Switzerland.

More context: the L-Carnitine compound page, all human trials.